Next 10 |
home / stock / cybn / cybn articles
As the premier gathering of top entrepreneurs and investors took place on Monday in New Jersey, we thought it would be a good time to scroll throug...
Florida-based cannabis company Kaya Holdings Inc ., AKA KAYS, (OTCQB:KAYS) has been awarded a license by the Oregon Health Authority to operate ...
Welcome to Benzinga’s psychedelic headlines roundup. This is our pick of must-read news items from the last two weeks of March 2024. See prev...
Psychedelics biotech Cybin Inc. (NYSE:CYBN) has received clearance from the Food and Drug Administration (FDA) on its Investigational New Drug (IND...
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.&nbs...
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD A decade after it was founded as a wholly-owned ...
The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substance...
Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) announced positive safety and efficacy data from its Phase 1 studies of CYB004 (intravenou...
A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Public Benefit...
News, Short Squeeze, Breakout and More Instantly...
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental-health disorders, is reporting its audited financial results for the fiscal year en...
- Received U.S. Food and Drug Administration (“FDA”) Breakthrough Therapy Designation (“BTD”) for CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of Major Depressive Disorder (“MDD”) - - Clinical si...
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, will be spotlighted during an upcoming online fireside chat at the H.C. Wa...